ইউরোপীয় ইউনিয়ন - পর্তুগীজ - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunossupressores - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

bristol-myers squibb farmacÊutica ltda - abatacepte - antinflamatorios antireumaticos

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

abbvie farmacÊutica ltda. - upadacitinibe hemi-hidratado - imunossupressores seletivos

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

pfizer brasil ltda - citrato de tofacitinibe - imunosupressor

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

laboratÓrios pfizer ltda - citrato de tofacitinibe - imunosupressor

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

eli lilly do brasil ltda - baricitinibe - agentes antineoplÁsicos e imunomoduladores; antagonistas hormonais e agentes relacionados; inibidores enzimÁticos; terapia endÓcrina

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

produtos roche quÍmicos e farmacÊuticos s.a. - tocilizumabe - antinflamatorios antireumaticos

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - golimumabe - antinflamatorios

ব্রাজিল - পর্তুগীজ - ANVISA (Agência Nacional de Vigilância Sanitária)

eli lilly do brasil ltda - ixequizumabe - imunomodulador

ইউরোপীয় ইউনিয়ন - পর্তুগীজ - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 e 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.